#OnWatch: July 12, 2016
CytRx Corporation (CYTR) 0.82 CYTR, a tiny biotech company specializing in oncology got hammered yesterday after they reported their product candidate, aldoxorubicin, failed to perform better than other typically used drugs. CYTR dropped -64% and set a new 52Wk Lo of 0.80 after hours following a brief halt and could be due for a dead-cat bounce. Other failed clinical trial tickers like EBIO had their legs cut out from under them and took some time to regroup before providing gains of over [...]